Kura Oncology (KURA) Expected to Release Earnings on Thursday

Kura Oncology (NASDAQ:KURA) is projected to release its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.89) per share and revenue of $20.1630 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 12:30 PM ET.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.83) EPS for the quarter, beating the consensus estimate of ($0.88) by $0.05. The company had revenue of $18.27 million during the quarter, compared to analysts’ expectations of $25.97 million. Kura Oncology had a negative net margin of 411.19% and a negative return on equity of 141.95%. On average, analysts expect Kura Oncology to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Kura Oncology Stock Performance

NASDAQ:KURA opened at $8.93 on Thursday. The company has a fifty day simple moving average of $10.27 and a two-hundred day simple moving average of $9.27. The company has a market cap of $792.72 million, a price-to-earnings ratio of -2.67 and a beta of 0.35. The company has a quick ratio of 6.14, a current ratio of 6.15 and a debt-to-equity ratio of 0.09. Kura Oncology has a 52 week low of $5.45 and a 52 week high of $12.49.

Analyst Ratings Changes

A number of research analysts recently issued reports on KURA shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kura Oncology in a report on Friday, July 17th. Wells Fargo & Company set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. CLSA set a $24.00 price target on Kura Oncology in a report on Thursday, June 4th. Lake Street Capital assumed coverage on Kura Oncology in a research report on Tuesday, April 14th. They issued a “buy” rating and a $23.00 price target on the stock. Finally, Wedbush reiterated an “outperform” rating and issued a $36.00 price objective on shares of Kura Oncology in a research note on Tuesday. Ten research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Kura Oncology presently has a consensus rating of “Moderate Buy” and an average target price of $25.46.

Insider Buying and Selling at Kura Oncology

In other news, insider Mollie Leoni sold 84,929 shares of the firm’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $9.82, for a total value of $834,002.78. Following the sale, the insider directly owned 182,345 shares in the company, valued at approximately $1,790,627.90. This trade represents a 31.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Several large investors have recently bought and sold shares of KURA. State of Wyoming boosted its position in shares of Kura Oncology by 57.9% during the 4th quarter. State of Wyoming now owns 19,224 shares of the company’s stock worth $200,000 after acquiring an additional 7,052 shares in the last quarter. Quarry LP purchased a new position in shares of Kura Oncology in the 3rd quarter valued at about $188,000. The Manufacturers Life Insurance Company raised its position in shares of Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company’s stock worth $175,000 after acquiring an additional 2,976 shares in the last quarter. Amundi acquired a new stake in shares of Kura Oncology during the 2nd quarter worth about $157,000. Finally, Strs Ohio acquired a new stake in shares of Kura Oncology during the 1st quarter worth about $143,000.

Kura Oncology Company Profile

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.